| Literature DB >> 10499914 |
Abstract
The majority ( approximately 70%) of postselection CD4(+) single-positive (SP) thymocytes are CD8(lo)CD4(hi). These cells express very low levels of CD8, undetectable by flow cytofluorimetric (FCM) analysis, but sufficiently high to allow purification by panning. Unlike the fully mature CD8(-)CD4(hi) thymocytes, which account for the remaining approximately 30% of the SP CD4(+) thymocytes, CD8(lo)CD4(hi) cells are functionally immature and short-lived unless they receive an unidentified maturation signal from the thymus. In this study, we tested the hypothesis that this signal is provided by a T cell receptor (TCR)-major histocompatibility complex (MHC) class II interaction. Using intrathymic transfer, we show that the immature CD8(lo)CD4(hi) cells could complete their intrathymic maturation and populate the peripheral lymphoid organs in the absence of MHC class II (and class I) molecules. Furthermore, in mice devoid of class II (and class I) molecules, the progeny of CD8(lo)CD4(hi) cells was long-lived and functionally reactive to allogeneic class II molecules, although their numbers in the spleen and the mesenteric lymph node were approximately 40-50% lower than those in class II(+) mice 5 mo after transfer. Control experiments demonstrated that the surviving cells did not originate from the contaminating mature thymocytes. These results demonstrate that the final maturation, proliferation, and peripheral survival (up to 5 mo) of at least some postselection CD4(+) SP cells do not require the TCR-MHC class II interaction. They also indicate that the TCR-MHC class II interaction(s) required for the intrathymic development of long-lived CD4(+) SP cells occurs before the CD4(hi) SP stage of development.Entities:
Mesh:
Substances:
Year: 1999 PMID: 10499914 PMCID: PMC2195626 DOI: 10.1084/jem.190.6.757
Source DB: PubMed Journal: J Exp Med ISSN: 0022-1007 Impact factor: 14.307
Functional Characterization of the CD8loCD4hi and CD8−CD4hi Thymocyte Subsets Isolated in This Study
| Donor cells | Mouse no. | Percent donor CD4+ cells in | ||
|---|---|---|---|---|
| Exp. 1 | mLN | Spleen | ||
| CD8−CD4hi | 1 | 7.0 | 2.0 | |
| 2 | 11.0 | 3.0 | ||
| Mean | 9.0 ± 2.0 | 2.5 ± 0.3 | ||
| CD8loCD4hi | 1 | 0.2 | 0.0 | |
| 2 | 0.6 | 0.1 | ||
| 3 | 0.8 | 0.0 | ||
| 4 | 0.5 | 0.0 | ||
| 5 | 0.0 | 0.0 | ||
| Mean | 0.4 ± 0.4 | 0.0 ± 0.1 | ||
| Exp. 2 | ||||
| CD8−CD4hi | 1 | 6.3 | 2.0 | |
| 2 | 5.5 | 1.9 | ||
| 3 | 7.2 | 2.5 | ||
| Mean | 6.3 ± 0.9 | 2.2 ± 0.3 | ||
| CD8loCD4hi | 1 | 0.0 | 0.0 | |
| 2 | 0.0 | 0.0 | ||
| 3 | 0.0 | 0.0 | ||
| Mean | 0.0 ± 0.0 | 0.0 ± 0.0 | ||
2 × 106 donor B6.Ly-5.2 cells of either subset were injected in the tail vein of B6 mice that were previously thymectomized, and depleted of CD4 cells by mAb treatment. 4 mo (Exp. 1) or 5 mo (Exp. 2) later, the recipients were analyzed by FCM, using CD4 and Ly-5 allele–specific antibodies, as described in Materials and Methods.
CD8loCD4hi Thymocytes Do Not Require MHC Class II Molecules for Final Intrathymic Maturation and Survival in the Peripheral Lymphoid Organs
| Exp. 1 | Recipients | Mouse no. | Percent donor CD4+ cells in | No. of donor CD4+ cells (Spleen + mLN × 106) | |
|---|---|---|---|---|---|
| mLN | Spleen | ||||
| Class II+ | 1 | 12.5 | 5.4 | 4.7 | |
| 2 | 12.9 | 3.4 | 3.7 | ||
| 3 | 12.0 | 4.6 | 5.1 | ||
| Mean | 12.5 ± 0.5 | 4.5 ± 1.1 | 4.5 ± 0.8 | ||
| Class II− | 1 | 6.9 | 2.3 | 2.7 | |
| 2 | 5.5 | 2.3 | 3.3 | ||
| 3 | 5.3 | 2.1 | 2.3 | ||
| Mean | 5.9 ± 1.0 | 2.2 ± 0.2 | 2.8 ± 0.5 | ||
| Intrathymic transfer | Mouse no. | CD4+ B6 cells in spleen | CD4+ B6.PL cells in spleen | ||
| Exp. 2 | Percent | No. × 106 | No. × 106 | ||
| 100% B6 | 1 | 1.9 | 2.5 | N/A | |
| →MHC I+II− | 2 | 2.3 | 2.9 | N/A | |
| 3 | 2.0 | 2.3 | N/A | ||
| Mean | 2.1 ± 0.2 | 2.6 ± 0.3 | N/A | ||
| 99% B68lo + | 1 | 1.7 | 2.5 | N/D | |
| 1% B6.PL CD8− | 2 | 2.1 | 2.9 | N/D | |
| →MHC I+II− | 3 | 1.7 | 2.1 | N/D | |
| Mean | 2.2 ± 0.5 | 2.5 ± 0.4 | N/D | ||
| 90% B68lo + | 1 | 2.1 | 1.9 | 0.07 | |
| 10% B6.PL CD8− | 2 | 1.7 | 1.5 | 0.05 | |
| →MHC I+II− | 3 | 1.8 | 1.8 | 0.06 | |
| Mean | 1.9 ± 0.3 | 1.7 ± 0.2 | 0.07 ± 0.01 | ||
| 100% B6 | 1 | 4.2 | 9.0 | N/A | |
| →MHC I−II− | 2 | 4.1 | 7.3 | N/A | |
| 3 | 3.8 | 11.2 | N/A | ||
| 4 | 3.5 | 8.8 | N/A | ||
| 5 | 2.9 | 6.9 | N/A | ||
| Mean | 3.7 ± 0.6 | 8.6 ± 1.7 | N/A | ||
In Exp. 1, 2 × 106 donor B6.Ly-5.2 CD8loCD4hi cells were injected intrathymically into CD4−/− class II+ (Class II+) or class II−/− (Class II−) Ly-5.1 recipients. For Exp. 2, CD8loCD4hi CD11c− class II− cells were isolated from B6 mice by cell sorting at >99% purity (with class II+, CD11b+, and CD11c+ cells undectable by FCM) and were injected into MHC class II− recipients alone, or after mixing with 1 or 10% CD8−CD4lo cells from B6.PL mice, to control for the level of possible contamination and outgrowth. An aliquot of CD8loCD4lo cells was also injected into CI/II− recipients. Cell number was always kept constant at 8.5 × 105. The recipients were analyzed 5 mo later, as described in Materials and Methods. Results are represen-tative of two experiments. The percentage of CD4+Ly-5.1+ (host) cells in unmanipulated control mice of the recipient type was 0.0 in the peripheral organs of CD4−/− class II+ mice, up to 1.7 ± 0.5 in the class II− mice and <0.1 in CI/II− mice. This background was subtracted from the results. N/A, not applicable; ND, not detectable.
The Progeny of Intrathymically Transferred CD8loCD4hi Develops into Functional CD4+ Peripheral T Cells Regardless of the Presence of MHC Class II Molecules
| Exp. 1 | CD4 donors | Stimulator cells | |||
|---|---|---|---|---|---|
| Control | B6 | bm12 | bm1 | ||
| B6 | 420 | 580 |
| ND | |
| CD8lo→class II+ | 340 | 870 | 8,010 | ND | |
| CD8lo→class II− | 340 | 380 | 5,520 | ND | |
| bm12 | 400 |
| 890 | ND | |
| Exp. 2 | |||||
| B6 | 990 | 1,560 |
| 2,300 | |
| CD8lo→class II+ | 560 | 980 | 6,750 | 1,180 | |
| CD8lo→class II− | 790 | 1,200 | 5,300 | 1,050 | |
| bm12 | 1,060 | 17,660 | 570 | 870 | |
Tissue culture supernatants from the above MLRs were collected after 96 (Exp. 1) or 72 h (Exp. 2), and assayed for the IL-2 content as described in Materials and Methods. Shown are the mean cpm from triplicate determinations. SD did not exceed 10% in any combination. Results are representative of three experiments. The numbers denoting significant proliferation are in bold.
Figure 1FCM profile of purified CD8loCD4hi thymocytes used for intrathymic injection. Total B6.Ly-5.2 thymocytes were fractionated by cytotoxic depletion of CD8hi cells with mAb + C′, followed by panning for the cells coated with the antibody and therefore still expressing low levels of CD8, and the final immunomagnetic sorting step using two rounds of purification with anti-CD4 mAb–coated paramagnetic beads (Miltenyi Biotec). (A) Obtained cells were stained for the expression of CD4 and CD8, and the FCM profile is shown in the figure as the 12% probability plot using the Lysys II® software program (Becton Dickinson). These cells were then used for the intrathymic and intravenous transfer in Exp. 2 shown in Table Table Table . Percentages denote the distribution of cells into the four major CD8/4-defined populations. (B) Histograms depicting expression of CD45RB on CD8−CD4hi (thick line, MFI = 341) and CD8loCD4hi thymocytes (thin line, MFI = 151) isolated as described in Materials and Methods. Cells were stained to reveal expression of CD4, CD8, and CD45RB, and the results were obtained without gating on CD4 cells, because virtually all cells were CD8−CD4+ by FCM.